TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

Lapshina, S.; Дубинина, Т. В.; Бадокин, В. В.; Бочкова, А. Г.; Бугрова, О. В.; Гайдукова, И. З.; Годзенко, А. А.; Дубиков, А. А.; Иванова, О. Н.; Korotaeva, T.; Несмеянова, О. Б.; Nikishina, Irina; Оттева, Э. Н.; Раскина, Т. А.; Ребров, А. П.; Румянцева, О. А.; Ситало, А. В.; Смирнов, А. В.; Эрдес, Ш. Ф.

doi:10.14412/1995-4484-2016-1s-75-79

Cited by 8 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Advances in understanding the immunopathogenesis of AxSp have served as the basis for the development of new therapies aimed at neutralizing the activity of these pro-inflammatory cytokines [2,12]. The appointment of biological disease-modifying antirheumatic drugs (bDMARDs) allows to quickly reduce the clinical and laboratory disease activity, improve quality of life and slow radiographic AxSp progression [2,7]. Despite the high efficiency, it has been reported failure of TNFα or IL-17 inhibitors in a significant percentage of AxSp patients [1,4,10].…”

Section: Introductionmentioning

confidence: 99%

Myeloid-derived suppressor cells as biomarkers of the effectiveness of therapy with new biological agents in axial spondyloarthritis

et al. 2023

View full text Add to dashboard Cite

Innate immune cells, including myeloid cells — myeloid derived suppressor cells (MDSCs) — are supposed to play an important role in the pathogenesis of axial spondyloarthritis (AxSp). Myeloid derived suppressor cells represent a heterogeneous population of immature cells capable of suppressing innate and adaptive immune responses with the most pronounced suppressor activity against T cells. Biological disease-modifying antirheumatic drugs (bDMARDs) can reduce the clinical and laboratory disease activity, but their effectiveness varies widely in different patients with AxSp. The present study is aimed at studying MDSCs subpopulations and their suppressive function depending on the response to bDMARD therapy in AxSp. The study included AxSp patients with a disease duration of 16.5 years (median); HLA-B27 (+) status was detected in 79% of cases. All patients received bDMARDs at least the past 12 weeks, including TNF inhibitors (etanercept, certolizumab pegol, adalimumab, or golimumab) or IL-17 inhibitors (secukinumab, ixekizumab, or netakimab). Percentage of granulocytic MDSCs (G-MDSCs, Lin-HLA-DR-CD33+CD66b+), monocytic MDSCs (M-MDSCs, HLA-DRlow/-CD14+), MDSCs of early stage differentiation (E-MDSCs, Lin-HLA-DR- CD33+CD66b-), as well as intracellular expression of arginase-1 was assessed by flow cytometry. Frequency of circulating MDSC subpopulations of patients with a stable response to bDMARDs (responders) did not differ significantly compared to healthy donors. Patients not responding to bDMARDs therapy showed increased relative and absolute number of E-MDSCs compared to healthy donors (pU = 0.01 and pU = 0.02, respectively) and the responders (pU = 0.03 and pU = 0.07, respectively). Increased percentage of E-MDSCs was positively correlated to disease activity — ESR (Rs = 0.821; p = 0.023), CRP (Rs = 0.714; p = 0.07) and ASDASCRP (Rs = 0.829; p = 0.042) in the non-responder group. Responder patients exhibited no correlation between disease activity and circulating MDSCs. The suppressor potential of MDSCs was analyzed by the intracellular expression of arginase-1 molecule which is involved in the inhibition of T cell response. Patients with the stable response were characterized by increased expression of arginase-1 in E-MDSCs compared to donors (pU = 0.02). Non-responders did not demonstrate significant changes in Arg-1 expression, however, the percentage of arginase-1-expressing G-MDSCs was positively correlated to indexes ASDASESR (Rs = 0.857; p = 0.014) and BASDAI (Rs = 0.785; p = 0.036). Thus, E-MDSCs as well as arginase-1 expression in MDSCs may serve as biomarkers of effectiveness bDMARD therapy, and act as potential candidate predictors of response to therapy in AxSp.

show abstract

Section: Introductionmentioning

confidence: 99%

Myeloid-derived suppressor cells as biomarkers of the effectiveness of therapy with new biological agents in axial spondyloarthritis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Пациентам с активным АС при неадекватном ответе на НПВП и не-фармакологическое лечение рекомендована терапия ингибиторами фактора некроза опу-холи α (ФНОα) [3]. Несмотря на значитель-ную эффективность ингибиторов ФНОα при лечении АС [4][5][6][7][8][9], у них имеются определен-ные ограничения и недостатки.…”

unclassified

Anti-Interleukin-17 Monoclonal Antibody for the Treatment of Ankylosing Spondylitis: Results of Analysis of a Russian Patient Group From the Randomized, Double-Blind, Placebo-Controlled Measure 1 and Measure 2 Trials

Эрдес¹,

Denisov²,

Маслянский³

et al. 2017

rsp

Self Cite

View full text Add to dashboard Cite

The effectiveness of IL-17 and TNF-α inhibitors in the treatment of ankylosing spondylitis

Dvornikova

2024

Clinical Medicine and Pharmacology

View full text Add to dashboard Cite

show abstract

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

Cited by 8 publications

References 39 publications

Myeloid-derived suppressor cells as biomarkers of the effectiveness of therapy with new biological agents in axial spondyloarthritis

Myeloid-derived suppressor cells as biomarkers of the effectiveness of therapy with new biological agents in axial spondyloarthritis

Anti-Interleukin-17 Monoclonal Antibody for the Treatment of Ankylosing Spondylitis: Results of Analysis of a Russian Patient Group From the Randomized, Double-Blind, Placebo-Controlled Measure 1 and Measure 2 Trials

The effectiveness of IL-17 and TNF-α inhibitors in the treatment of ankylosing spondylitis

Contact Info

Product

Resources

About